Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever

Rosemary Wyber, Ben Boyd, Samantha Colquhoun, Bart Currie, Mark Emmanuel Engel, Joseph Kado, Ganesan Karthikeyan, Mark Sullivan, Anita Saxena, Meru Sheel, Andrew Steer, Joseph Mucumbitsi, Liesl Zuhlke, Jonathan Carapetis

Research output: Contribution to journalArticlepeer-review

Abstract

Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with global experts in rheumatic heart disease on the characteristics of benzathine penicillin G formulations which could be changed to improve adherence with secondary prophylaxis. Characteristics included dose interval, pain, administration mechanism, cold chain independence and cost. A sample target product profile for reformulated benzathine penicillin G is presented.
Original languageEnglish
Pages (from-to)572-578
Number of pages7
JournalDrug Delivery and Translational Research
Volume6
Issue number5
DOIs
Publication statusPublished - Oct 2016

Fingerprint

Dive into the research topics of 'Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever'. Together they form a unique fingerprint.

Cite this